You are here

Article Text

Article menu
Download PDFPDF
Letter
Combined aspirin and clopidogrel in cataract surgical patients: a new risk factor for ocular haemorrhage?
  1. B R Davies
  1. Hull and East Yorkshire Eye Hospital, Fountain Street, Hull HU3 2JZ, UK
  1. Correspondence to: B R Davies Hull and East Yorkshire Eye Hospital, Fountain Street, Hull HU3 2JZ, UK; bryn.dukonline.co.uk

https://doi.org/10.1136/bjo.2004.045997

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi) is a thienopyridine with antiplatelet effects caused by its inhibition of ADP mediated platelet aggregation pathways.1 Both aspirin and clopidogrel have established benefits in the secondary prevention of fatal and non-fatal coronary and cerebrovascular events.1,2 The CURE study has concluded that combining low dose aspirin and clopidogrel in patients with acute coronary syndromes results in additional improvements in outcome over aspirin alone.3 We can therefore expect increasing numbers of ophthalmic patients who have been started on this combined treatment (“COM”).

    Departmental concerns were raised by experience with a 76 year old normotensive patient who was on COM. He …

    View Full Text